Our CEO in Conversation
Chief Executive Officer Dr. Wolfgang Wienand about Siegfried’s journey in 2022 and its priorities in the year to come.
Media Release from May 4, 2023
Siegfried acquires majority stake in DiNAMIQS to establish a best-in-class development and manufacturing organization for cell and gene therapies
Media Release from April 25, 2023
Siegfried begins construction of a new global R&D Center for Drug Substances in Evionnaz
Media Release from March 9, 2023
Siegfried opens global Development Center for Drug Products in Barcelona
Come and find out more about a company with a strong tradition of innovation where you really can “expect more”.
Come and find out more about a company with a strong tradition of innovation where you really can “expect more”.
Explore more about how our broad range of customer development services, drug substance & drug product manufacturing and packaging capabilities together with our existing product portfolio may help you achieve greater value.